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large body of evidence has emerged to suggest
an extensive comorbidity between depression and car-
diovascular disease (CVD).Cross-sectional and prospec-
tive analyses have shown that depression may increase
mortality and morbidity in patients with heart failure,
regardless of its etiology, and independently of tradi-
tional cardiovascular factors.
1Although this may be the
result of psychological factors such as contemplation of
one’s mortality and changes in lifestyle and social rela-
tionships,there is now compelling evidence that a recip-
rocal relationship between both disorders exists. The
presence of cardiovascular disease can influence mood
states,
2 and some of the factors associated with depres-
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There is increasing knowledge regarding the considerable comorbidity between depression and cardiovascular dis-
ease, which are two of the most common disorders in developed countries. The associated vulnerability is not unidi-
rectional, as the presence of cardiovascular disease can also influence mood states. Although this may be the result of
psychological factors, common biological mechanisms, including genetic ones, are thought to be responsible for this
interaction; we can thus question whether variations in genes could be predisposing factors. Regarding the multiple
interactions in the mechanisms between depression and cardiovascular system disorders, eg, dysfunctions in the hypo-
thalamic-pituitary-adrenocortical and sympathoadrenal axis and the response to stress, the importance of the sero-
tonergic and immune systems, or the impact on the renin-angiotensin system, several candidate genes are being inves-
tigated. However, despite the interest in unraveling the potential susceptibility genes for both disorders, most available
studies have so far dealt with the impact of polymorphisms in relation to either depression or cardiovascular disease.
A few recent studies have now examined the effects of gene-gene or gene-environment interactions, and are inves-
tigating the impact of “depression-related” variants on cardiac response to stress. The first promising results were
obtained with the serotonin transporter, and it may be hypothesized that this polymorphism interacts via the impact
of the S allele on depression and via the effect of the L allele on platelet activation. However, the role played by var-
ious other candidate genes remains to be determined, especially regarding the question as to whether they are indica-
tive of common pathophysiological mechanisms, or for identifying a subgroup of patients with somatic disorders that
are more closely related to psychiatric symptoms.     
© 2007, LLS SAS Dialogues Clin Neurosci. 2007;9:19-28.acute and chronic stress,may give rise to vascular disor-
ders such as atherosclerosis, microcirculatory endothe-
lial dysfunction,or metabolic conditions such as diabetes
and dyslipidemia.
3
Concerning the importance of biologic vulnerability fac-
tors and environment,it was proposed that a substantial
proportion of comorbidities may be attributed to a few
underlying liability factors that are applicable to both
cardiovascular and depressive disorders.
4 Thus, even if
both conditions did not affect each other,they might still
cosegregate if they shared common underlying factors,
including genetic ones.As both disorders are complex
and multifactorial in origin, involving multiple genes
with interactive or additive effects together with envi-
ronmental factors,depression and cardiovascular disease
could be different manifestations of the same genetic
substrate.
Interacting pathophysiological mechanisms
Although the interacting mechanisms have not been
fully elucidated,there is much evidence for this interac-
tion.Both disorders have been shown to run in families,
and twin studies have provided evidence that this famil-
ial aggregation is based on an increased genetic vulner-
ability.
5,6 Interestingly, only one study investigated the
association between depressive symptoms,hypertension,
and heart disease in male mono- and dizygotic twin pairs
to analyze the genetic and/or environmental effects.
Thus,Scherrer et al
7 found that heart disease and hyper-
tension were significantly associated with up to five
symptoms of depression,and concluded that the lifetime
co-occurrence of heart disease and depression could best
be explained by a substantial genetic contribution,but
not by a contribution from the shared environment.The
data from this study strongly suggest common genetic
influences across depression and CVD.
Potential candidate genes may be identified on the basis
of the various direct and indirect mechanisms which
have been proposed as possible substrates for the inter-
action between depression and CVD (Figure 1).Among
them are hyperactivity of the noradrenergic and hypo-
thalamic-pituitary-adrenal (HPA) systems,
8 reduced
heart rate variability,myocardial ischemia and ventricu-
lar instability in response to psychological stress, and
depression-related exaggerated platelet activity,as well
as enhanced inflammatory-mediated atherogenesis.
8,9
The relationship between the immune,autonomic,neu-
roendocrine,and neurotransmitter processes is multidi-
rectional; psychological factors act on the neuroen-
docrine,neurotransmitter,and immune systems and vice
versa,thereby influencing vulnerability to affective and
cardiovascular disorders.Further impact may be exerted
by risk factors common to both disorders,such as smok-
ing,reduced exercise,metabolic disturbances,or antide-
pressant cardiotoxicity.
10As all these pathways,and even
the reaction to environmental stimuli, are genetically
regulated, it is plausible that a common genetic vulner-
ability is likely to account for the observed association
between depression and CVD.
11 Although genes con-
tributing to the risk for both disorders have so far not
been investigated simultaneously as common comorbid
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Figure 1. Interacting pathophysiological mechanisms. CNS, central




















behavioral changesGenes of the serotonergic pathway
The neurotransmitter serotonin (5-HT) is essential for a
large number of psychological and physiological
processes, including the regulation of appetite, mood,
anxiety,cognition,and wakefulness,as well as vascular
smooth muscle contraction or modulation of platelet
aggregation.
12 In depression research,a number of alter-
ations have been reported of 5-HT uptake and trans-
porter and receptor binding sites in the brain and periph-
ery,
13,14 as well as altered platelet activation.
15 Moreover,
reduced serotonergic function within the central nervous
system (CNS) has been associated with alterations in the
HPA response to stress,thus predicting higher rates of
coronary heart disease (CHD) and increased mortality.
16
With respect to the key position of 5-HT in physiologi-
cal and psychological processes, it is not surprising that
genes coding for the serotonergic pathway have repeat-
edly been investigated for several years.These include
not only a possible association with psychiatric states
such as anxiety,hostility,depression,or smoking behav-
ior, but also several characteristics of platelet function
or the effect of 5-HT on the vessel wall and induction of
atherosclerosis.
The 5-HT transporter
The 5-HT transporter (5-HTT) clears the synaptic cleft
of neurotransmitters and thus limits the duration of 5-HT
function.As 5-HTT is not only expressed on neuronal tis-
sues but also on blood platelets, where it is crucial in
maintaining the homeostasis of 5-HT,
17 this gene has
become an important candidate for both disorders.
Further,although the expression of 5-HTT is predomi-
nantly under genetic control,nongenetic factors,includ-
ing psychoactive drugs,stress,alcohol,and dietary factors,
also regulate its expression.
18
One polymorphic site in particular within the 5-HTT
gene, located in the promoter region with a
deletion/insertion variation of 44 bp,creating short (S)
and long (L) alleles,the 5-HTT-linked promoter region
(5-HTTLPR), has been the subject of most investiga-
tions.
19The presence of the S allele of the HTTLPR was
associated with decreased transcriptional activity and
decreased 5-HT uptake,which,in turn,results in longer
duration of the serotonergic activity.
20
The 5-HTTLPR has been multiply investigated in psy-
chiatric disorders.Although the results are not conclu-
sive,and differential data were obtained concerning the
association of the HTTLPR with depression or suicidal-
ity, there is now no doubt that this polymorphism is
involved in complex phenomena,such as cognition,tem-
perament,character,and the regulation of emotion.
21-23
Following the first observation that individuals carrying
at least one S allele of the 5-HTTLPR displayed higher
levels of trait anxiety,“neuroticism,”“harm avoidance,”
and depressive symptoms than those with homozygosity
for the long allele (L/L),
21 many studies followed to con-
firm this observation, and recent meta-analyses have
demonstrated a significant association between the S
allele and increased neuroticism or harm avoidance (for
review see refs 24,25).
The impact of the 5-HTTLPR in CVD has been investi-
gated for several years. In concordance with the
increased transcriptional activity of the L allele, it was
shown that LL homozygous subjects have higher blood
5-HT concentrations than those with the S allele, pre-
sumably due to increased 5-HT uptake and storage.
26
These findings are in agreement with the observation in
geriatric depressed patients that homozygosity for the
long allele was associated with platelet activation, and
increased platelet factor 4 and thromboglobulin levels.
27
Thus, platelets of persons with the L/L genotype are
more efficient in uptake and storage of 5-HT in their
dense granules,followed by increased 5-HT release upon
activation, which may consequently lead to greater
thrombus formation.This hypothesis was underlined in
a multicenter study in more than 600 patients with coro-
nary artery disease,as carriers of the LL genotype had
a higher risk for myocardial infarction,with an odds ratio
of 1.4 (95% CI 1.11 to 1.76).
28
5-HT not only has effects on platelets, but also has a
direct proliferative action on smooth muscle cells.
Increased uptake and storage of 5-HT has repeatedly
been discussed as a pathophysiological mechanism of
pulmonary hypertension,and indeed,an increased inci-
dence of LL homozygotes among patients with pul-
monary hypertension was observed;in those patients the
pulmonary artery smooth muscle cells showed increased
5-HT uptake and increased proliferation in response to
5-HT.
29This is a clinical relationship between a genetic
abnormality and a cellular process critical for the devel-
opment of pulmonary vascular disease.
Interestingly,the S allele was also found to increase the
risk for cardiac events via its impact on emotion. In a
prospective study investigating patients after acute
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21myocardial infarction, Nakatani and colleagues were
able to show that the S allele conferred increased risk
for subsequent cardiac events, being mediated by the
development of depressive symptoms which were sig-
nificantly higher among S allele carriers.
30A significant
association between the 5-HTTLPR S allele and the
incidence of poststroke major depression underlines
the importance of the reciprocal relationship on a
genetic basis.
31Altogether,these findings might lead to
the speculation that the HTTLPR contributes to the
risk for CVD with both the S- and L allele, with the L
allele working via platelet activation and the S allele
contributing via the increased susceptibility for depres-
sion.
The 5-HTTLPR and response to stress
The possible impact of the 5-HTTLPR polymorphism on
the effects of central 5-HT on cardiovascular reactivity
in response to mental stress was investigated in healthy
volunteers.Subjects with one or two L alleles had higher
cerebrospinal fluid levels of the 5-HT metabolite 5-
hydroxyindole-acetic acid (5-HIAA) than those with the
S/S genotype,and exhibited increased blood pressure and
increased heart rate responses to a mental stress.
16
Comparable results were obtained in a further study
investigating the cardiovascular response during a psy-
chological challenge in relation to the 5-HTTLPR geno-
types. Young healthy male L allele carriers showed
increased heart rate reactivity in response to stress,an
association that could not be shown in female L allele
carriers.This finding could thus at least partly explain the
sex differences in heart rate response.
32
The link between depression and CVD is strengthened
by the recent evidence for a gene-environment interac-
tion. Investigating a large representative cohort in a
prospective longitudinal study, Caspi and colleagues
33
were able to show that individuals with one or two copies
of the S allele exhibited more depressive symptoms,more
diagnosable depression,and more suicidality in relation
to stressful life events than individuals homozygous for
the L allele.This finding suggests that genetic variants
may act to promote resistance to environmental influ-
ences. In addition, the study by Grabe et al
34 demon-
strated this gene–environment interaction in relation to
the 5-HTTLPR genotypes in a cohort with severe men-
tal (eg, unemployment, disrupted social network) and
physical (eg,myocardial infarction,stroke,diabetes,and
degenerative diseases) distress.They found significant
interactions between the 5-HTTLPR S allele and unem-
ployment or chronic disease, but only in females.This
finding not only confirms previous findings for a signifi-
cant gene-environment interaction of the S allele,but it
also indicates a higher mental vulnerability to social
stressors and chronic disease.
The 5-HTTLPR and risk factors for cardiovascular 
disease
Smoking is one of the unquestioned risk factors for
CVD,and dependence on tobacco,like many other drug
dependencies, is a complex behavior with both genetic
and environmental factors contributing to its variance.
35
As there is increasing evidence that chronic nicotine
abuse decreases 5-HT levels in the brain
36 and selective
serotonin reuptake inhibitors (SSRIs), combined with
a 5-HT1 receptor antagonist, may reverse the reward
deficits during withdrawal in rats,
37 the 5-HTT gene has
attracted attention. Furthermore, it is well known that
smoking behavior is common among depressed
patients.
For the Japanese population a relationship between the
L allele, myocardial infarction, and smoking was sug-
gested, as the LL and LS genotypes were more fre-
quently observed in male CVD patients, and smoking
had a synergistic effect.
38 In contrast, in the American
population Lerman found no significant difference in the
distribution of 5-HTT genotypes among smokers and
nonsmokers,but revealed an interaction between the SS
genotype and neuroticism in nicotine addiction.
39
Recently, in the Caucasian population no association
between the 5-HTTLPR genotypes and smoking behav-
ior was found.
40 These discrepant findings suggest that
nicotine addiction may be influenced by a combination
of the 5-HTT gene and anxiety-related personality traits,
rather than by each factor alone.
35 Furthermore, alco-
holism,a known risk factor for hypertension and cerebral
hemorrhagic infarction and a common comorbid condi-
tion with depression, has been associated with the SS
genotype in an American population.
41
Integration of the findings with the 5-HTTLPR
As so far no association studies have been carried out
with both CVD and depression, it is hard to assess the
validity of the separate findings as common genetic risk
Basic research
22factors. Nevertheless, the convincing data for the 5-
HTTLPR as a susceptibility locus for depression and
cardiovascular events might be judged as a common
mechanism,and could therefore be of theoretical inter-
est, suggesting an impact of the 5-HT transporter.The
fact that different alleles of this polymorphism were
associated with the different disorders,the S allele with
depression and anxiety personality traits and the L
allele with vascular events and atherosclerosis, seems
contradictory, but might be explained by the complex
nature of both disorders.Complex disorders are multi-
factorial in origin,involving the action of several genes
of minor effect together with environmental factors.
Thus,an interaction of several genes in particular,each
contributing to the risk for one disorder,could increase
the liability for both disorders. One example of this
might be the observation that the S allele could also
increase the risk for cardiac events via its impact on
emotion,
30 thus inducing a cascade of subsequent stress
reactions that themselves have negative input on the
vasculature and cardiac function.
Other serotonergic candidates 
In contrast to the data with 5-HTT, those for the sero-
tonergic receptor gene polymorphisms are less abundant.
The 5-HT2A receptor T102C polymorphism,which was
the subject of many pharmacogenetic investigations,was
not found to be a susceptibility locus for unipolar or
bipolar depression,
42,43 and its importance for CVD is
completely unresolved.
11 Nevertheless,on the basis that
depression appears to be associated with an increased
susceptibility for 5-HT-mediated platelet activation,
mediated via the 5-HT2A receptors,this receptor might
contribute to an increased risk of thromboembolic events
in patients with depression and CVD.
44 Thus, this gene
could be seen as important candidate for future investi-
gations.
Concerning a structural variant of the 5-HT2C receptor
gene,which gives rise to a cysteine to serine substitution
in the N terminal extracellular domain of the receptor
protein (Cys23Ser),a significant excess of the 23Ser allele
carriers was found among a large European cohort of
depressive patients.
45 This finding is interesting with
respect to the development of diabetes and obesity,since
two polymorphisms within the promoter region of the 5-
HT2C receptor gene have recently been associated with
obesity and/or type 2 diabetes.
46
Immune activation in depression and 
cardiovascular disease
It is now established that a relationship exists between
depression and inflammation,
47 which might be seen as a
process involved in the development or progression of a
number of comorbid diseases.A variety of immunologic
processes are altered in depression, including those of
cellular components and soluble mediators, such as
acute-phase proteins and cytokines (eg,interleukin [IL]-
1,IL-6,and tumor necrosis factor [TNF]-α).
48,49The most
consistent finding in depression,an increase in IL-6 dur-
ing the acute state, is remarkable, as IL-6 is one of the
main stimulators of C-reactive protein (CRP),which was
also found to be increased during depression.
50
Cytokines induce neuroendocrine and central neuro-
transmitter alterations that are reminiscent of those seen
in depression,and these alterations are exacerbated by
stressors.
47,49 Both IL-1 and IL-6 stimulate corticotropin-
releasing hormone (CRH) secretion, resulting in
increased adrenocorticotropic hormone (ACTH) and
glucocorticoid release.On the other hand,proinflamma-
tory cytokines, such as IL-1, IL-6, or TNF-α, have pro-
found effects on peripheral and brain serotonergic sys-
tems,as they increase extracellular 5-HT concentration
within different brain regions or modulate the activity of
the 5-HTT.
51
Inflammation is considered to be involved in most stages
of atherosclerosis,from initial recruitment of leukocytes
to the formation of atherosclerotic plaques.
52
Proatherosclerotic factors acting on the endothelium
result in chronic inflammation,with a consequent rise of
C-reactive protein,adhesion molecules,and the proin-
flammatory cytokines TNF-α and IL-6.
53,54
With respect to the fact that the expression and function
of cytokines is highly genetically influenced,several stud-
ies have been performed to investigate the influence of
genes coding for cytokines on CVD and diabetes or obe-
sity.The most extensively studied polymorphism of the
IL-6 gene is a G/C conversion in the promoter region
(–174G/C),which alters the cyclic AMP (cAMP) binding
site and affects the transcription and plasma level of IL-
6.
54Though some negative results were also reported in
patients with coronary artery disease and previous
myocardial infarction,there is now a consensus that,at
least in man,the –174C allele is associated with increased
plasma CRP and IL-6 concentrations,
55 with higher sys-
tolic blood pressure,
56 especially above a body mass index
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23of 25,and with an increased risk of coronary heart dis-
ease.
57 Smoking appears to have an additive effect on
these associations,as both an increase in blood pressure
and a detrimental effect on endothelial function was
observed in –174CC carriers.
58 Obesity (an expansion of
the adipose tissue closely related to insulin resistance)
was also shown to be related to the IL-6 –174C allele,as
the GG genotype is more common among lean male sub-
jects with low concentrations of either insulin or glu-
cose.
59A relationship was shown between alcohol con-
sumption and clinical cardiovascular events and carotid
atherosclerosis,as in subjects with a daily alcohol con-
sumption of ≥30 g and with the CC genotype,there were
significantly higher plasma IL-6 levels and carotid artery
intima-media thickness.
60
The data with TNF-α gene polymorphisms are less abun-
dant.TNF-α is involved in the inflammation process of
atherosclerosis and lipid metabolism.A common poly-
morphism in the promoter region (-308 G/A) regulates
the TNF-α production and was shown to be a candidate
gene for the development of both obesity and insulin
resistance.
61 In an Australian population, it was shown
that subjects who were homozygous for the -308A allele
had higher fasting insulin levels, higher systolic blood
pressure,and lower high-density-lipoprotein (HDL) lev-
els than subjects homozygous for the -308G allele.Thus,
this variant conveys an increased risk for the develop-
ment of insulin resistance in obese subjects, and low
HDL levels further increase the risks associated with
insulin resistance in A allele carriers.
62
Unfortunately, to date only a few inflammation genes
related to CVD have also been examined in depression.
For the IL-1BC to T substitution at position -511 (C-
511T),there is literature suggesting that the -511C allele
is more prevalent among patients with dysthymia,
63 and
might be associated with the severity of depressive symp-
toms,
64 even in patients with Alzheimer’s disease.
65 For
the TNF-α gene polymorphism,the -308A allele,which
was associated with enhanced inflammatory response
after cardiac surgery
66 was proposed to influence depres-
sive symptoms.
67The genes of other inflammatory mark-
ers have not yet been examined in depression.
Angiotensin-converting enzyme gene
Angiotensin-converting-enzyme (ACE) is a membrane-
bound endopeptidase which is involved in the metabo-
lism of many small peptides, such as the generation of
angiotensin II or bradykinin,both being important for
the regulation of vascular tone and cardiac functions.In
addition,angiotensin II has proinflammatory actions in
the vascular wall, inducing the production of IL-6 and
adhesion molecules, and thus augmenting vascular
inflammation, inducing endothelial dysfunction and
enhancing the atherogenesis process.
68 However, the
effects of this enzyme are not restricted to the vascula-
ture,as the renin-angiotensin system (RAS) exists within
the CNS,with multiple effects on different systems.
69
The most extensively investigated polymorphism of ACE
is the insertion (I) or deletion (D) of a 287 bp Alu repeat
sequence within intron 16 of the gene,and the D allele is
associated with increased levels of circulating ACE.
70
There has been considerable interest in the potential
associations of this polymorphism with CVD,including
myocardial infarction,hypertension,and left ventricu-
lar hypertrophy,but the associations were not consistent
for all disorders.A review of the literature revealed a
moderate degree of increased risk for myocardial infarc-
tion associated with the ACE DD genotype in most pop-
ulations,especially in the Japanese.
71
There was also one study suggesting that the ACE geno-
types confer susceptibility to depression, with an over-
representation of the DD genotype in Japanese
depressed patients,
72 a finding which could not be repli-
cated in an European population.
73 However, we have
observed that patients with the I/I genotype responded
more rapidly to antidepressant treatment.
73,74
Furthermore we were able to demonstrate the interac-
tion with the HPA axis, as patients with the DD geno-
type had higher basal and stimulated cortisol levels in
the combined dexamethasone–CRH suppression test.
75
Recently the impact of the ACE DD genotype on
myocardial infarction was re-evaluated using the para-
digm of gene-gene interaction.In patients with or with-
out coronary artery disease,the ACE insertion/deletion
polymorphism was investigated, together with a func-
tional polymorphism in the G-protein β-3 subunit
(C825T),which had earlier been associated with hyper-
tension and obesity.
76This analysis revealed the highest
odds ratio (OR=7.5) in patients also with the combined
homozygous Gβ3 825TT and ACE DD genotypes,sug-
gesting a significant interaction of the Gβ3 825T and the
ACE D alleles as possible contributing factors for
myocardial infarction.
76 Based on our own previous
results concerning an association of the Gβ3 825T allele
with affective disorders
77 and a possible influence of the
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24ID polymorphism of the ACE gene polymorphism on
therapeutic outcome in affective disorders,
73 we studied
the interaction of both genes in 201 patients with unipo-
lar major depression and 161 ethnically matched controls.
Interestingly,in depressed patients we also observed a
combined action of ACE and Gß3 genotypes,as ACE-ID
and DD/Gβ3-TT carriers were more than four times
more frequent among the patient group compared with
controls.
78 As our study was carried out in depressed
patients with no serious CVD,we are presently unable to
predict whether this combined action of the ACE
ID/DD-Gβ3 TT genotype increases the risk for both dis-
orders.Nevertheless,our study reports for the first time
that the same allelic combination of two genes that have
been shown to increase the risk for myocardial infarc-
tion
79 also increase the vulnerability for depression,and
this could be a link to explain the comorbidity of depres-
sion with CVD.
The findings with the ACE gene were further extended
in our recent study,where we were able to associate one
single-nucleotide polymorphism (SNP) in the promoter
region of the ACE gene (rs4291) with an A/T transition
in two independent large case-control samples of
patients suffering from major depression.We have fur-
ther observed that the T allele of this variant was not
only associated with depression,but also with the serum
ACE concentration and with hypercortisolism during
the acute state of the disorder.
80 This finding suggests
that the SNP rs4291 might therefore represent a com-
mon pathophysiological link for depression and CVD.
This hypothesis is supported by another observation
from our group, as we found that in a proportion of
patients the initially increased serum CRP levels did not
decrease during effective antidepressant treatment,and
these constantly increased CRP levels can be associated
to both, the ACE D allele and the RS4291T allele.
81
Summary and conclusions
Despite the interesting and promising genetic findings on
depression and cardiovascular disorders,and despite the
considerable overlap in the pathophysiological mecha-
nisms of these disorders,up to now few studies have been
carried out to investigate a possible combined genetic
mechanism.Considering the fact that both disorders are
complex traits resulting from multiple genotypes,and from
gene-gene as well as gene-environment interactions,the
identification of a liability gene for either disorder is dif-
ficult.Some multifactorial disorders,rather than resulting
from variations in many genes of small effect,may result
from variations in fewer genes whose effects are condi-
tional on exposure to environmental risks.
33 In recent years,
many studies have investigated polymorphisms in candi-
date genes in relation to functional characteristics of cen-
tral or peripheral mechanisms which are involved in the
development of CVD.The fact that many of these genes
are also discussed as liability genes for depression raises
the intriguing question whether an interactive or synergis-
tic effect is responsible for the bidirectional relationship.
Prospective studies in a reasonable number of patients,
including intensive clinical characterization,the investi-
gation of biological markers in both patient groups,and
genotyping for relevant polymorphisms in genes which
are assumed to be involved in both disorders will have to
be carried out to shed more light on the interaction
between depression and CVD. ❏
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Factores genéticos comunes para la 
depresión y la enfermedad cardiovascular
Existe un creciente conocimiento relacionado con la
considerable comorbilidad entre la depresión y la
enfermedad cardiovascular, dos de las enfermedades
más comunes en los países desarrollados. La vulne-
rabilidad asociada no es unidireccional, ya que la pre-
sencia de enfermedad cardiovascular también puede
afectar el estado de ánimo. Aunque esto puede ser
el resultado de factores psicológicos, se piensa que
los mecanismos biológicos comunes, incluyendo los
de tipo genético, serían responsables de esta inte-
racción y es posible preguntarse si las variaciones en
los genes podrían ser factores predisponentes. En
relación con las interacciones múltiples en los meca-
nismos entre la depresión y los trastornos del sistema
cardiovascular (como disfunciones en los ejes hipo-
tálamo-hipófisis-adrenocortical y simpático-adrenal
y la respuesta de estrés, la importancia de la seroto-
nina y el sistema inmune, o el impacto del sistema
renina angiotensina) se están estudiando diversos
genes candidatos. Sin embargo, a pesar del interés
por identificar ciertos potenciales genes de suscepti-
bilidad para ambos trastornos, la mayoría de los
estudios disponibles a la fecha han abordado el
impacto del polimorfismo en relación con la depre-
sión o con la enfermedad cardiovascular. Unos pocos
estudios recientes han examinado los efectos de las
interacciones genes-genes o genes-ambiente y están
investigando el impacto de las variantes “relaciona-
das con la depresión” en la respuesta cardíaca al
estrés. Los primeros resultados promisorios se obtu-
vieron con el transportador de serotonina y se puede
hipotetizar que este polimorfismo interactúa
mediante el impacto del alelo S en la depresión y por
el efecto del alelo L en la activación plaquetaria. Sin
embargo, el papel que puedan tener otros genes
candidatos aun debe ser determinado, especial-
mente en relación con la pregunta de si acaso ellos
representan mecanismos fisiopatológicos comunes y
también si permiten identificar un subgrupo de
pacientes con trastornos somáticos que tienen mayor
relación con síntomas psiquiátricos.   
Facteurs génétiques communs à la 
dépression et aux maladies cardiovasculaires
L’importante comorbidité entre la dépression et les
maladies cardiovasculaires, deux des maladies les
plus répandues dans les pays développés, est de
mieux en mieux connue. La présence d’une mala-
die cardiovasculaire peut également influer sur l’hu-
meur, la vulnérabilité associée n’est donc pas uni-
directionnelle. Cette interaction pourrait être due
à des mécanismes psychologiques, mais des méca-
nismes biologiques pourraient constituer des fac-
teurs prédisposants, génétiques par exemple.
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patho-adrénergique, la réponse au stress, l’impor-
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